Therefore, even if inhibitors of P-gp and ABCG2 do not ultimately prove useful for MDR cancers directly, they may prove to be efficacious as tools to increase the bioavailability of chemotherapeutic agents to sites protected by endogenously expressed ABC transporters, such as the central nervous system and the gut. The gene discussed is ABCG2; the disease is cancer.